Table 5.
Association of CRP polymorphisms and renal outcomes
| CRP SNPs and Genotype | N | Composite of Halving Your GFR, Reaching ESRD, or Death |
|
|---|---|---|---|
| Hazard Ratio (95% CI) | P Valuesa | ||
| rs2808630 | |||
| AA | 439 | Ref | |
| AG | 191 | 0.87 (0.59–1.29) | 0.49 |
| GG | 15 | 3.65 (1.62–8.23) | 0.002b |
| rs1205 | |||
| GG | 447 | Ref | |
| AG | 179 | 1.14 (0.74–1.52) | 0.48 |
| AA | 25 | 0.90 (0.36–2.27) | 0.84 |
| ss3093066 | |||
| CC | 399 | Ref | |
| AC | 213 | 1.02 (0.6–1.5) | 0.89 |
| AA | 37 | 1.23 (0.6–2.5) | 0.56 |
| rs1417938 | |||
| AA | 503 | Ref | |
| AT | 141 | 0.89 (0.58–1.37) | 0.62 |
| TT | 6 | 1.07 (0.14–7.89) | 0.94 |
| rs3093058 | |||
| AA | 423 | Ref | |
| AT | 204 | 0.81 (0.55–1.19) | 0.28 |
| TT | 20 | 0.92 (0.28–3.02) | 0.89 |
| rs1800947 | |||
| GG | 644 | Ref | |
| CG | 7 | 0.19 (0.03–1.14) | 0.11 |
| CC | NA | NA | |
Composite outcome = decrease in GFR by 50% or a drop in the GFR ≥25 ml/min per 1.73 m2, ESRD, or death.
Hazard ratios are adjusted for age, gender, BP treatment assignment, drug treatment assignment, body mass index, baseline GFR, baseline proteinuria, smoking, and number of comorbidities.
Ref, reference group homozygous for the major allele; NA, not applicable.
a
Unadjusted for multiple comparisons.
b
Statistical significance at an α=0.0045 after Bonferroni correction for 11 genotypes.